Skip to main content
. 2021 Jan 1;11(4):1763–1779. doi: 10.7150/thno.47057

Figure 8.

Figure 8

MiR-30b-3p overexpression correlates with poor prognosis and adverse response to TMZ of GBM patients. (A) Expression of miR-30b-3p in the Chinese Glioma Genome Atlas (CGGA) cohort of human high-grade and low-grade glioma patients. (B) Overall survival (OS) of GBM patients receiving TMZ treatment with high or low miR-30b-3p expression. (C) HIF1α, miR-30b-3p expression (FISH), RHOB, Ki-67 and cleaved caspase 3 in clinical samples from GBM patients, who had received TMZ-based chemotherapy. Scale bars, 25 µm (FISH) and 50 µm (IHC). Three replicates per sample, three independent experiments per sample. (D) Expression of miR-30b-3p in the clinical samples from primary and recurrent GBM patients. (E) Overall survival (OS) of GBM patients, who received TMZ treatment with low (n = 30) miR-30b-3p expression. (F) Overall survival (OS) of GBM patients, who received TMZ treatment with high (n = 30) miR-30b-3p expression. (G) Overall survival (OS) of GBM patients, who received TMZ treatment with high (n = 7) or low (n = 7) cerebrospinal fluid (CSF) miR-30b-3p expression. (H) Overall survival (OS) of GBM patients who received TMZ treatment with high (n = 7) or low (n = 7) serum miR-30b-3p expression, ***P < 0.001.